Day: July 29, 2020

Total contract drilling revenues were $930 million (total adjusted contract drilling revenues of $983 million), compared with $759 million in the first quarter of 2020 (total adjusted contract drilling revenues of $807 million);Revenue efficiency(1) was 97.2%, compared with 94.4% in the prior quarter;Operating and maintenance expense was $525 million, compared with $540 million in the prior period;Net loss attributable to controlling interest was $497 million, $0.81 per diluted share, compared with net loss attributable to controlling interest of $392 million, $0.64 per diluted share, in the first quarter of 2020;Adjusted net loss was $1 million, excluding $496 million of net unfavorable items. This compares with adjusted net loss of $187 million, $0.30 per diluted share, in the previous quarter;Adjusted EBITDA was $418 million, compared...

SAN DIEGO, July 29, 2020 (GLOBE NEWSWIRE) — Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, today announced that Richard W. Pascoe, President and Chief Executive Officer of Histogen, will present at the Canaccord Genuity 40th Annual Growth Conference.  The virtual presentation is scheduled for Wednesday, August 12, 2020 at 1:30 p.m. Eastern Time.Presentation DetailsFor those not available to listen to the live broadcast, a replay will be archived for 90 days and available through the Investors page on www.histogen.com.About Histogen Inc.Histogen Inc. is a clinical-stage therapeutics company focused on developing potential first-in-class restorative...

 Westwood SmallCap Fund Introduces Y Share ClassWestwood SmidCap Fund Introduces Ultra Share ClassTrading outsourced to improve client experience and internal operational efficiencyDALLAS, July 29, 2020 (GLOBE NEWSWIRE) — Westwood Holdings Group, Inc. (NYSE: WHG) today reported second quarter 2020 earnings. Highlights from the quarter include:Income Opportunity, Enhanced Balanced, SmallCap Value, Alternative Income, Global Convertible, LargeCap Select and Total Return strategies beat their primary benchmarks for the quarter.Income Opportunity, Enhanced Balanced, Alternative Income, Global Convertible, MLP Opportunities and Total Return strategies achieved top quartile institutional rankings.Revenues of $15.9 million compared with $16.7 million in the first quarter of 2020 and $21.7 million a year ago.Net loss of $2.6 million compared...

HOUSTON, July 29, 2020 (GLOBE NEWSWIRE) — Crown Castle International Corp. (NYSE: CCI) (“Crown Castle”) today reported results for the second quarter ended June 30, 2020 and maintained its full year 2020 Outlook, with the exception of a reduction to net income.(a) Attributable to CCIC common stockholders.(b) See “Non-GAAP Financial Measures, Segment Measures and Other Calculations” included herein for further information and reconciliation of this non-GAAP financial measure to net income (loss).(c) As issued on April 29, 2020.“In the second quarter, we generated solid results that were in line with our expectations as our business continues to perform well during this period of unprecedented uncertainty,” stated Jay Brown, Crown Castle’s Chief Executive Officer. “We continue to anticipate...

SAN DIEGO, July 29, 2020 (GLOBE NEWSWIRE) — Retail Opportunity Investments Corp. (NASDAQ:ROIC) announced today financial and operating results for the three and six months ended June 30, 2020, and provided information regarding financial and operational activities in light of the ongoing COVID-19 pandemic.SECOND QUARTER 2020$4.6 million of net income attributable to common stockholders ($0.04 per diluted share)$29.2 million of Funds From Operations (FFO)(1) ($0.23 per diluted share)81.9% of total 2Q 2020 billed base rent has been paid to date97.0% portfolio lease rate at June 30, 20208.4% increase in same-space comparative cash rents on new leases (7.2% on renewals)9.3% decrease in same-center cash net operating income (2Q‘20 vs. 2Q‘19)3.1% decrease in same-center cash net operating income (first 6 months of ‘20 vs. ‘19)COVID-19...

HOUSTON, July 29, 2020 (GLOBE NEWSWIRE) — Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, today announced that it has commenced an underwritten public offering of shares of its common stock.  All of the shares are being offered by Salarius.  The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.Ladenburg Thalmann & Co. Inc. is acting as sole book-running manager in connection with the public offering.A shelf registration statement on Form S-3 (File No. 333-231010) relating to the shares was filed with the Securities and Exchange Commission (the “SEC”) and was declared effective by the SEC on May 17, 2019....